Filing Details
- Accession Number:
- 0000950170-23-072381
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-21 20:27:23
- Reporting Period:
- 2023-12-19
- Accepted Time:
- 2023-12-21 20:27:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1805387 | Cerevel Therapeutics Holdings Inc. | CERE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1830371 | Mark Bodenrader | C/O Cerevel Therapeutics Holdings, Inc. 222 Jacobs Street, Suite 200 Cambridge MA 02141 | See Remarks | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-12-19 | 14,199 | $0.00 | 20,528 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-12-19 | 5,085 | $0.00 | 25,613 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-12-20 | 7,889 | $41.42 | 17,724 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2023-12-19 | 14,199 | $0.00 | 14,199 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-12-19 | 5,085 | $0.00 | 5,085 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct | ||
| 0 | No | 4 | M | Direct |
Footnotes
- In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest.
- Each RSU represented the contingent right to receive one share of the Issuer's common stock.
- Includes 807 shares previously acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.
- The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
